ABSTRACT
Background and purpose: To investigate the reproducibility of deep-inspiration breath hold (DIBH) breast cancer treatments on Halcyon™ performed using the first clinical version of AlignRT InBore™ (Vision RT Ltd., London, UK), a Halcyon's SGRT dedicated solution. Materials and methods: The ease and feasibility of DIBH treatments was retrospectively investigated for the initial 22 left breast cancer patients treated on Halcyon™ using AlignRT InBore™. Setup time, Cone beam computed tomography (CBCT) imaging and analysis time as well as overall treatment time were recorded. Online and offline review of CBCT images was undertaken to verify the compliance of breast, heart, spine, sternum and diaphragmatic domes positions. Results: Mean duration of patient setup, CBCT analysis and overall treatment time were 4 min, 1.1 min and 14 min respectively. Online review of 520 CBCT acquisitions by therapists showed minimal positioning shifts with AlignRT InBore™ guidance with mean value of vertical, longitudinal, and lateral shifts of 1.7 mm, -1.7 mm, and -0.2 mm respectively. Meanwhile, offline review of 115 CBCTs by the radiation oncologist, showed reproducible breath hold (BH) with average deviation of breast, heart, spine, sternum and diaphragmatic domes respectively within 2.4 mm, 2.9 mm, 3.3 mm, 3.2 mm and 4.5 mm in magnitude. Conclusion: AlignRT InBore™ allows for accurate and reproducible DIBH on Halcyon™ with breast and heart organs' positions within 3 mm in magnitude of expected position and fully compliant with planning margins (5 mm anisotropic CTV-PTV margins).
ABSTRACT
The most prescribed type of psychotropic medication in maghrebian psychiatry is neuroleptics. It is therefore legitimate to study the epidemiology of the most frequent side-effect of long-term treatment with neuroleptics: Tardive Dyskinesia (TD). At the moment, a collaborative study is under way on epidemiology of TD within the framework of the Maghrebian Association of Biological Psychiatry; several studies have also been conducted on this topic in the University Psychiatric Centre Ibn Rochd, Casablanca, Morocco in 1984, 1986 and 1987. For the maghrebian study, only preliminary results from Tunis will be presented. These studies have been interested in two epidemiological aspects: prevalence of TD in hospitalized and out-patients treated with neuroleptics; prevalence of TD-like movements among never treated schizophrenics. The assessment tool used for all the studies was the Abnormal Involuntary Movement Scale (AIMS). Main results of these studies are: 1) General prevalence of TD and risk factors in neuroleptized patients: In Tunis, Douki and Benamor in their on-going study, found a general prevalence of 20.50% (N = 200 in patients). A multi-factor analysis showed that risk factors are (in decreasing order): female gender, age above 60, associated depression, total duration of neuroleptic treatment above 20 years, a frequently discontinued treatment, shock therapies in antecedents or associated, a diagnosis of non schizophrenic psychosis, haloperidol intake below 25 mg and fluphenazine depot above 100 mg daily. In Casablanca, in 1984, Chorfi found a general prevalence of 10% (N = 50 out-patients). In 1986, Bentounsi found a 14.50% prevalence in Casablanca (N = 400 out-patients) and 63.97% in the oldest psychiatric hospital in Morocco in Berreshid (N = 605 in-patients).(ABSTRACT TRUNCATED AT 250 WORDS)
